

Ulenistamab

Cat. No.:	HY-P99537
CAS No.:	2415259-90-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research ^[1] .
In Vitro	Ulenistamab (PBP1510) suppresses the proliferation of the PC cell lines (CFPAC-1 and BxPC-3). The migration and invasion of PC cell lines is significantly reduced ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Pharmacokinetic (PK) characteristics and immunogenicity of PBP1510 (up to 20 mg/kg), are examined in single dose studies in 6 monkeys. In monkey studies, a dose-proportional increase in systemic exposure was observed at low and high doses ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kedar Diwakar Mandakhalikar, et al. First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. *Journal of Clinical Oncology* 2022 40:16_suppl, e16274-e16274.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA